2-[4-(benzyloxy)phenyl]ethanethiol | 549494-36-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-[4-(benzyloxy)phenyl]ethanethiol
• 英文别名: 2-(4-phenylmethoxyphenyl)ethanethiol
• CAS: 549494-36-2
• 化学式: C₁₅H₁₆OS
• 分子量: 244.357
• InChiKey: XEYZPGMLBNJLJP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  10.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-[4-(benzyloxy)phenyl]ethanethiol 在 palladium on activated charcoal 氢氧化钾 、 氢气 、 间氯过氧苯甲酸 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 60.0 ℃ 、344.73 kPa 条件下， 反应 5.0h， 生成 4-[2-(Tetrahydro-furan-2-ylmethanesulfonyl)-ethyl]-phenol
  参考文献：
  名称：

  Synthesis of a series of compounds related to betaxolol, a new .beta.1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases

  摘要：

  A series of para-substituted phenoxypropanolamines has been synthesized and tested for beta-adrenoceptor blocking activity. Some derivatives (8, 11, 12, 20, 21) exhibited greater in vitro potency than the reference drugs metoprolol and propranolol. This series, in contrast to propranolol but similar to metoprolol, possesses cardioselectivity. The 3-[p-[(cycloalkylmethoxy)ethyl]phenoxy]-1-substituted-amino-2-prop anol derivatives 8 (cyclopropylmethoxyethyl: betaxolol) and 11 (cyclobutylmethoxyethyl) produced antihypertensive effects in spontaneously hypertensive rats. Betaxolol (Kerlon, 8) was found to exhibit an appropriate preclinical pharmacological and human pharmacokinetic profile (elevated oral bioavailability and prolonged plasma half-life) for the treatment of chronic cardiovascular diseases such as hypertension and angina.

  DOI：

  10.1021/jm00389a008
• 作为产物：
  描述：

  S-(2-[4-(benzyloxy)phenyl]ethyl) ethanethioate 在 sodium thiomethoxide 、 盐酸 作用下， 以 甲醇 、 水 为溶剂， 反应 0.5h， 以80%的产率得到2-[4-(benzyloxy)phenyl]ethanethiol
  参考文献：
  名称：

  [EN] THERAPEUTIC AGENTS
  [FR] AGENTS THERAPEUTIQUES

  摘要：

  3-苯基丙酸衍生物的替代物，制备这种化合物的过程，它们在治疗包括脂质紊乱（血脂异常）在内的临床疾病中的用途，无论是否伴随胰岛素抵抗，其治疗用途的方法以及含有它们的药物组合物。

  公开号：

  WO2004113282A1

文献信息

• [EN] AMINE SALTS OF (-)-2-{`2-(4-HYDROXYPHENYL) ETHYL!-THIO}-3-`4-(2-{4-`(METHYLSULFONYL)OXY! PHENOXY}ETHYL)PHENYL! PROPANOIC ACID AND THERE USE IN MEDICINE<br/>[FR] SELS AMINE D'ACIDE (-)-2-{`2-(4-HYDROXYPHENYL)ETHYL!-THIO}-3-`4-(2-{4-`(METHYLSULFONYL)OXY!PHENOXY}ETHYL)PHENYL!PROPANOIQUE ET LEUR UTILISATION EN MEDECINE
  申请人：ASTRAZENECA AB

  公开号：WO2004113283A1

  公开（公告）日：2004-12-29

  A tert-butylamine salt, a piperazine salt, a choline salt, a tris(hydroxymethyl)methylamine salt, a lysine salt or an adamantylamine salt of (-)-2-[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid processes for their preparation, their use in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance and other manifestations of the metabolic syndrome, and pharmaceutical compositions containing them.

  一种(-)-2-[2-(4-羟基苯基)乙基]硫基}-3-[4-(2-4-[(甲磺氧基)氧基]苯氧基}乙基)苯基]丙酸的叔丁胺盐、哌嗪盐、胆碱盐、三(羟甲基)甲基胺盐、赖氨酸盐或金刚烷胺盐的制备方法，以及它们在治疗临床病症中的应用，包括与胰岛素抵抗和代谢综合征其他表现有关的脂质紊乱（脂质代谢异常），以及含有它们的药物组合物。
• [EN] POTASSIUM OR SODIUM SALT OF (-)-2-{`2-(4-HYDROXYPHENYL)ETHYL!-THIO-3-`4-(2-{4-`(METHZLSULFONZL) OXY !PHENOXY}PHENYL!PROPANOIC ACID AND THEIR USE IN MEDICINE<br/>[FR] SEL DE POTASSIUM OU DE SODIUM DE L'ACIDE (-)-2-{`2-(4-HYDROXYPHENYL)ETHYL!-THIO-3-`4-(2-{4-`(METHYLSULFONYL) OXY !PHENOXY}ETHYL)PHENYL!PROPANOIQUE ET UTILISATION DE CELUI-CI EN MEDECINE
  申请人：ASTRAZENECA AB

  公开号：WO2004113284A1

  公开（公告）日：2004-12-29

  A potassium salt or a sodium salt of (-)-2-[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid, processes for their preparation, their use in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance and other manifestations of the metabolic syndrome, and pharmaceutical compositions containing them.

  (-)-2-[2-(4-羟基苯基)乙基]硫代}-3-[4-(2-4-[(甲磺氧基)氧基]苯氧基}乙基)苯基]丙酸的钾盐或钠盐，其制备方法，它们在治疗包括脂质紊乱（脂质代谢异常）在内的临床病症中的应用，无论是否伴随胰岛素抵抗和代谢综合征的其他表现，并含有它们的药物组合物。
• [EN] PROCESS FOR THE PREPARATION OF RACEMIC 2-{[2-(4-HYDROXYPHENYL)ETHYL]THIO}-3-[4-(2-{4-[(METHYLSULFONYL)OXY]PHENOXY}ETHYL)PHENYL]-PROPANOIC ACID<br/>[FR] PROCEDE D'ELABORATION D'ACIDE RACEMIQUE 2-{[2-(4-HYDROXYPHENYL)ETHYL]THIO}-3-[4-(2-{4-[(METHYLSULFONYL)OXY]PHENOXY}ETHYL)PHENYL]-PROPANOIQUE
  申请人：ASTRAZENECA AB

  公开号：WO2004113285A1

  公开（公告）日：2004-12-29

  The present invention provides a process for the preparation of substantially racemic 2-[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]-propanoic acid which comprises reacting 2-[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid enriched in one enantiomer with a base in an inert solvent.

  本发明提供了一种制备基本外消旋的2-[2-(4-羟基苯基)乙基]硫}-3-[4-(2-4-[(甲基磺酰氧)苯氧基]乙基}苯基)丙酸的方法，其包括将富含一种对映体的2-[2-(4-羟基苯基)乙基]硫}-3-[4-(2-4-[(甲基磺酰氧)苯氧基]乙基}苯基)丙酸与惰性溶剂中的碱反应。
• Process for the preparation of racemic 2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)pheyl]-propanoic acid
  申请人：Lindstedt-Alstermark Eva-Lotte

  公开号：US20060167309A1

  公开（公告）日：2006-07-27

  The present invention provides a process for the preparation of substantially racemic 2-[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]-propanoic acid which comprises reacting 2-[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid enriched in one enantiomer with a base in an inert solvent.

  本发明提供了一种制备基本为外消旋的2-[2-(4-羟基苯基)乙基]硫基}-3-[4-(2-4-[(甲基磺酰)氧]苯氧基}乙基)苯基]-丙酸的方法，包括将富含一种对映体的2-[2-(4-羟基苯基)乙基]硫基}-3-[4-(2-4-[(甲基磺酰)氧]苯氧基}乙基)苯基]丙酸与惰性溶剂中的碱反应。
• 3-Phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
  申请人：Alstermark Lindstedt Eva-Lotte

  公开号：US20050215630A1

  公开（公告）日：2005-09-29

  A compound of formula (I); wherein R 1 represents chloro, fluoro or hydroxy as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts, prodrugs, solvates and crystalline forms thereof, to processes for preparing such compounds, to their the utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  化合物公式(I)中，R1代表氯、氟或羟基，以及其光学异构体和外消旋体，以及药学上可接受的盐、前药、溶剂化合物和晶体形式，以及制备这些化合物的方法，它们在治疗临床疾病包括脂质紊乱（血脂异常）方面的用途，无论是否伴随胰岛素抵抗，以及用于治疗的方法和包含它们的药物组合物。